Compare ADMA Biologics Inc (ADMA) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs LYFT Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while LYFT Inc trades at $17.54 (market cap $6.53B). The key difference: LYFT Inc is far larger — about 3× ADMA Biologics Inc's market cap, and LYFT Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | LYFT | |
|---|---|---|
Market Cap | $2.18B | $6.53B |
Sector | Health | Industrials |
52-Week High | $20.38 | $24.57 |
52-Week Low | $7.60 | $12.65 |
Enterprise Value | $2.25B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Lyft trades at $17.46, up 7.12% in the past 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, though recent Q2 2026 earnings missed estimates. Positive cash flow trends and record active riders above 30 million signal operational strength, while an ongoing legal investigation presents a headwind.
The outlook is mixed: valuation ratios like P/E of 2.54 appear attractive, and analyst consensus targets $19.17, but earnings misses and competitive pressures weigh on sentiment. Key risks include fiduciary duty investigations and moderating booking growth, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
